David L Payne1, Anju Nohria2. 1. Cardio-Oncology Program, Brigham and Women's Hospital/Dana Farber Cancer Institute, 75 Francis Street, Boston, MA, 02115, USA. david.lee.payne@gmail.com. 2. Cardio-Oncology Program, Brigham and Women's Hospital/Dana Farber Cancer Institute, 75 Francis Street, Boston, MA, 02115, USA.
Abstract
PURPOSE OF REVIEW: Cardiomyopathy is a significant complication of various cancer treatments and has been best studied in patients receiving anthracyclines and trastuzumab. This paper evaluates strategies to prevent chemotherapy-induced cardiotoxicity. RECENT FINDINGS: Increasing cumulative anthracycline dose, use of ≥2 cardiotoxic therapies, extremes of age, and pre-existing cardiovascular risk factors, or established cardiovascular disease, heighten the risk of developing chemotherapy-induced cardiomyopathy. Continuous rather than bolus anthracycline infusions, liposomal doxorubicin, or concomitant dexrazoxane reduces chemotherapy-induced cardiotoxicity. Treatment with neurohormonal antagonists or statins and exercise training during chemotherapy are promising, but as yet unproven, cardioprotective strategies. Identification of high-risk patients and optimization of their underlying cardiovascular risk factors/disease are essential to prevent cardiotoxicity. In patients requiring high-dose anthracyclines, continuous infusions, liposomal doxorubicin, or dexrazoxane should be considered to mitigate cardiotoxicity. Current data do not support the routine use of neurohormonal antagonists or statins as cardioprotective agents in patients treated with cardiotoxic chemotherapies.
PURPOSE OF REVIEW: Cardiomyopathy is a significant complication of various cancer treatments and has been best studied in patients receiving anthracyclines and trastuzumab. This paper evaluates strategies to prevent chemotherapy-induced cardiotoxicity. RECENT FINDINGS: Increasing cumulative anthracycline dose, use of ≥2 cardiotoxic therapies, extremes of age, and pre-existing cardiovascular risk factors, or established cardiovascular disease, heighten the risk of developing chemotherapy-induced cardiomyopathy. Continuous rather than bolus anthracycline infusions, liposomal doxorubicin, or concomitant dexrazoxane reduces chemotherapy-induced cardiotoxicity. Treatment with neurohormonal antagonists or statins and exercise training during chemotherapy are promising, but as yet unproven, cardioprotective strategies. Identification of high-risk patients and optimization of their underlying cardiovascular risk factors/disease are essential to prevent cardiotoxicity. In patients requiring high-dose anthracyclines, continuous infusions, liposomal doxorubicin, or dexrazoxane should be considered to mitigate cardiotoxicity. Current data do not support the routine use of neurohormonal antagonists or statins as cardioprotective agents in patients treated with cardiotoxic chemotherapies.
Authors: Edith Pituskin; John R Mackey; Sheri Koshman; Davinder Jassal; Marshall Pitz; Mark J Haykowsky; Joseph J Pagano; Kelvin Chow; Richard B Thompson; Larissa J Vos; Sunita Ghosh; Gavin Y Oudit; Justin A Ezekowitz; D Ian Paterson Journal: J Clin Oncol Date: 2016-11-28 Impact factor: 44.544
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Am J Cardiol Date: 2011-03-02 Impact factor: 2.778
Authors: G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper Journal: N Engl J Med Date: 2000-04-13 Impact factor: 91.245
Authors: D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia Journal: Ann Intern Med Date: 1979-11 Impact factor: 25.391
Authors: Mark J Haykowsky; John R Mackey; Richard B Thompson; Lee W Jones; D Ian Paterson Journal: Clin Cancer Res Date: 2009-07-21 Impact factor: 12.531
Authors: Furqan Shaikh; L Lee Dupuis; Sarah Alexander; Abha Gupta; Luc Mertens; Paul C Nathan Journal: J Natl Cancer Inst Date: 2015-11-23 Impact factor: 13.506
Authors: M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler Journal: Ann Oncol Date: 2004-03 Impact factor: 32.976
Authors: Lucie Heinzerling; Patrick A Ott; F Stephen Hodi; Aliya N Husain; Azadeh Tajmir-Riahi; Hussein Tawbi; Matthias Pauschinger; Thomas F Gajewski; Evan J Lipson; Jason J Luke Journal: J Immunother Cancer Date: 2016-08-16 Impact factor: 13.751
Authors: Januar Wibawa Martha; Dery A Soedarsono; Mohammad Iqbal; Astri Astuti; Erwan Martanto; Mohammad Rizki Akbar; I Gede Sumantra Journal: Int J Cardiol Heart Vasc Date: 2020-07-03
Authors: Pablo Garcia-Pavia; Yuri Kim; Maria Alejandra Restrepo-Cordoba; Ida G Lunde; Hiroko Wakimoto; Amanda M Smith; Christopher N Toepfer; Kelly Getz; Joshua Gorham; Parth Patel; Kaoru Ito; Jonathan A Willcox; Zoltan Arany; Jian Li; Anjali T Owens; Risha Govind; Beatriz Nuñez; Erica Mazaika; Antoni Bayes-Genis; Roddy Walsh; Brian Finkelman; Josep Lupon; Nicola Whiffin; Isabel Serrano; William Midwinter; Alicja Wilk; Alfredo Bardaji; Nathan Ingold; Rachel Buchan; Upasana Tayal; Domingo A Pascual-Figal; Antonio de Marvao; Mian Ahmad; Jose Manuel Garcia-Pinilla; Antonis Pantazis; Fernando Dominguez; A John Baksi; Declan P O'Regan; Stuart D Rosen; Sanjay K Prasad; Enrique Lara-Pezzi; Mariano Provencio; Alexander R Lyon; Luis Alonso-Pulpon; Stuart A Cook; Steven R DePalma; Paul J R Barton; Richard Aplenc; Jonathan G Seidman; Bonnie Ky; James S Ware; Christine E Seidman Journal: Circulation Date: 2019-04-16 Impact factor: 29.690
Authors: Josefin Ansund; Sara Mijwel; Kate A Bolam; Renske Altena; Yvonne Wengström; Eric Rullman; Helene Rundqvist Journal: Cardiooncology Date: 2021-02-15